Skip to main content
Home
Latest news
Browse topics
Lupus Rheumatoid arthritis Spondyloarthropathies COVID-19 Browse all topics
In focus
Bimekizumab: Dual IL-17A/IL-17F inhibition in SpA Anifrolumab for the treatment of SLE JAK inhibitor safety: Weighing up the data and understanding the risks Rituximab and rheumatology practice in the COVID-19 era Safety snapshot: Upadacitinib in patients with PsA Repurposing rheumatology drugs for COVID-19 Telemedicine in rheumatology: COVID-19 and beyond Managing PsA in resource-limited settings
Conferences
ACR Convergence 2022 EULAR 2022 Congress
About us
Medicine Matters Rheumatology
EXTENDED SEARCH

15-06-2017 | EULAR 2017 | Video

EULAR 2017 highlights: Peter Nash

This activity is financially supported by Novartis Pharma AG

Related content

15-07-2019 | Rheumatoid arthritis | View from the clinic | Article

JAK inhibitors in rheumatoid arthritis

29-03-2019 | Rheumatoid arthritis | Feature | Article

JAK inhibitors in RA: A round-up of the phase 3 trials

25-06-2019 | Psoriatic arthritis | EULAR 2019 | News

Positive secukinumab results for axial manifestations in PsA

15-06-2019 | Psoriatic arthritis | EULAR 2019 | News

Ixekizumab tops adalimumab in head-to-head PsA trial
Image Credits